Speaker(s): 

Bianca Harper Rodriguez, PharmD, PGY1 resident, Geisinger - has nothing to disclose..

Moderator(s): 

Christopher J DeFrancesco PharmD, Geisinger - has nothing to disclose.

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

1. Define and distinguish tardive dyskinesia from parkinsonism and extrapyramidal symptoms 

2. Identify the common drug classes that can cause tardive dyskinesia 

3. Discuss the pathophysiology of tardive dyskinesia 

4. Review drugs commonly used for management of tardive dyskinesia 

5. Evaluate current literature and guidelines for the management of tardive dyskinesia

6. Discuss clinical considerations for patients and possible prevention

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Christopher DeFrancesco PharmD, RPH, Anil Singh MD, Roop Parlapalli, MD, FHM, FACP, Mary Ellen Berry PA-C, and Carlena Miller CRNP have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None